Fig. 6
From: Imatinib relaxes the pulmonary venous bed of guinea pigs
The role of PDGFR-β and interaction of ET-1 with PDGFR. a Effect of inhibition of PDGFR (imatinib) on the contractile effect of 10 nM PDGF-BB: (■) PV: PDGF-BB (10 nM) (n = 5); (□) PV: imatinib (100 μM), PDGF-BB (n = 5). b Effect of inhibition of PDGFR-α (ponatinib) and PDGFR-β (SU6668) on the contractile effect of PDGF-BB: (■) PV: PDGF-BB (100 nM) (n = 7); (□) PV: SU6668 (5 μM), PDGF-BB (100 nM) (n = 6); (
) PV: Ponatinib (100 nM), PDGF-BB (100 nM) (n = 7). c The relaxant effects of the unselective TKI imatinib and the PDGFR-β inhibitors SU6668 or DMPQ in ET-1 pre-constricted PVs: (■) PV 1 nM ET-1/imatinib (n = 5); (
) PV: 1 nM ET-1/SU6668 (n = 5); (□) PV: 1 nM ET-1/DMPQ (n = 5); (●) PV: 1 nM ET-1/ponatinib (n = 5); d The relaxant effect of the unselective TKI imatinib after inhibition of PDGFR-β by SU6668 or DMPQ: (■) PV: 5 μM SU6668/1 nM ET-1/imatinib; (□) PV: 5 μM DMPQ/1 nM ET-1/imatinib; e/f Effect of inhibition of PDGFR (imatinib), PDGFR-α (ponatinib) and PDGFR-β (SU6668) on ET-1 induced contraction: (■) PV: ET-1 (1 nM) (n = 5); (
) PV: 100 μM imatinib/1 nM ET-1 (n = 5); (
) PV: 1 μM imatinib/1 nM ET-1 (n = 5); (
) PV: 5 μM SU6668/1 nM ET-1 (n = 5); (
) PV: 100 nM ponatinib/1 nM ET-1 (n = 5). Statistics was performed by LMM (Fig. 6
a, b, e, f). Asterics indicate different EC50 values (Fig. 6
c, d). P <0.05 are considered as significant: *** < 0.001